Top news of the day from across the health care landscape.
The FDA has approved a labeling supplement for neratinib (Nerlynx, Puma Biotechnology) for the extended adjuvant treatment of human epidermal growth factor receptor 2-positive early stage breast cancer, Puma Biotechnology reported. According to the press release, the label now includes safety information based on interim results from the phase 2 CONTROL trial. Interim data from the trial showed that the addition of prophylactic treatment with loperamide plus budesonide reduced the discontinuation rate due to neratinib-associated diarrhea to 11% versus a discontinuation rate of 18% with loperamide alone.
A recent study found that individuals with HIV who received kidney transplants from deceased donors with HIV achieved long-term successful outcomes from the procedure, The American Journal of Managed Care reported. According to the article, the study followed 51 transplant recipients with HIV in South Africa, finding that after 5 years, 83.3% of participants were still alive and 78.7% still had a functioning transplanted kidney. At the time of transplantation, all patients had achieved viral suppression and there were not observed increases in viral load among those who maintained consistent use of antiretroviral therapy following the transplant, the article reported.
Walmart is rolling out a health care pilot program for its employees to connect with recommended providers based on effectiveness and cost-efficiency, The Associated Press reported. According to the article, the program will allow employees to connect with local physicians in areas such as primary care, cardiology, and obstetrics. Walmart will use data from public and private insurance plans to curate a list of recommended providers for employees, the article reported.